News

An 11-month-old partnership between UCSF and Pfizer, Inc., aimed at rapidly moving new therapies into human clinical trials, ... collaborative partnerships with industry.” The Pfizer and UCSF ...
With a market cap of $145.7 billion, Pfizer Inc. (PFE) is a global, research-driven biopharmaceutical company, specializing ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced strategic partnerships with ICON plc and PAREXEL International Corporation, both of which will serve as strategic providers of clinical trial ...
Pfizer Inc. (NYSE:PFE) today announced the creation of the Innovative Target Exploration Network (ITEN), a new, early-stage partnering model that enab ...
Biotech company Immunai, which developed an AI-based immune system mapping technology for drug development, announces the appointment of Dr. Mikael Dolsten to its board of directors.
Beam has received a $300m upfront payment from Pfizer, and if Pfizer proceeds into the clinic and late-stage trials with all three targets, a potential $1.3bn in milestone payments is on the table ...
Pfizer has always been a heavy user of CROs, and over the past few months it’s been ramping up its partnerships. Last month, it doubled down on its existing pact with Syneos Health (the results ...
Pfizer announced on Monday a new partnership with Beam Therapeutics, a Cambridge, Massachusetts-based biotech developing therapies based on its base-editing technology. To begin the alliance ...
Pharma’s got plenty of clinical trial data — but it wants to supplement with wearables data, explains Pfizer’s big data exec, Christopher Boone.
The story of two firms, Pfizer and Moderna, leading the race for approval of a COVID-19 vaccine Two companies, with deep Massachusetts ties, are leading the race for approval of a coronavirus vaccine.
Pfizer Inc., Astra Zeneca PLC and Eli Lilly and Co. are among the major international drug companies signing agreements with schools such as New York University, Harvard and the University of ...
NEW YORK, Sept 13 (Reuters) - The public has good reason to look beyond Pfizer Inc's disappointing track record in developing new medicines, the drugmaker's research chief told investors on Monday ...